New model-based analysis further supports the potential of TECVAYLI®▼ (teclistamab) plus daratumumab to redefine long-term survival expectations in early line relapsed/refractory multiple myeloma

Phase 3positiveTECVAYLI®daratumumabPositive

AI Analysis

Summary

Johnson & Johnson announced positive Phase 3 MajesTEC-3 data showing TECVAYLI (teclistamab) plus daratumumab achieved sustained disease control and survival benefit in relapsed/refractory multiple myeloma patients with 1-3 prior therapy lines.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

sustained disease control and survival demonstrated in MajesTEC-3 study

Importance:7/10

Sentiment:

0.75

multiple myelomacombination therapyearly relapse/refractorydata announcement

Related Companies

$JNJ

Read the original article

Published by GlobeNewswire Pharma on September 23, 2026 2:07 PM

Read Original